Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyGlimepiride
Identification
- Name
- Glimepiride
- Accession Number
- DB00222 (APRD00381)
- Type
- Small Molecule
- Groups
- Approved
- Description
Glimepiride is the first III generation sulphonyl urea it is a very potent sulphonyl urea with long duration of action.
- Structure
Structure for DB00222 (Glimepiride)
- Synonyms
- Glimepirida
- Glimépiride
- Glimepiridum
- External IDs
- HOE 490 / HOE-490
- Product Images
- Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Amaryl Tablet 1 mg Oral Sanofi Aventis 2002-03-12 Not applicable Canada 
Amaryl Tablet 1 mg/1 Oral Sanofi Aventis 2009-06-18 Not applicable US 
Amaryl Tablet 4 mg Oral Sanofi Aventis 2002-03-12 Not applicable Canada Amaryl Tablet 4 mg/1 Oral Sanofi Aventis 2009-06-18 Not applicable US Amaryl Tablet 2 mg Oral Sanofi Aventis 2002-03-12 Not applicable Canada Amaryl Tablet 2 mg/1 Oral Sanofi Aventis 2009-06-18 Not applicable US Co Glimepiride Tablet 4 mg Oral Cobalt Laboratories 2006-04-24 2012-08-02 Canada Co Glimepiride Tablet 2 mg Oral Cobalt Laboratories 2006-04-24 2012-08-02 Canada Co Glimepiride Tablet 1 mg Oral Cobalt Laboratories 2006-04-24 2012-08-02 Canada Sandoz Glimepiride Tablet 4 mg Oral Sandoz Canada Incorporated 2005-08-04 Not applicable Canada - Generic Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Apo-glimepiride Tablet 1 mg Oral Apotex Corporation 2007-09-29 Not applicable Canada Apo-glimepiride Tablet 4 mg Oral Apotex Corporation 2007-09-29 Not applicable Canada Apo-glimepiride Tablet 2 mg Oral Apotex Corporation 2007-09-29 Not applicable Canada Glimepiride Tablet 4 mg/1 Oral Pd Rx Pharmaceuticals, Inc. 2007-08-23 Not applicable US Glimepiride Tablet 1 mg/1 Oral Nucare Pharmaceuticals, Inc. 2007-08-23 Not applicable US Glimepiride Tablet 1 mg/1 Oral Aurobindo Pharma 2012-06-29 Not applicable US Glimepiride Tablet 4 mg/1 Oral Bionpharma Inc. 2015-10-01 Not applicable US Glimepiride Tablet 4 mg/1 Oral Remedy Repack 2013-05-14 2017-01-18 US Glimepiride Tablet 2 mg/1 Oral Micro Labs Limited 2013-06-13 Not applicable US Glimepiride Tablet 2 mg/1 Oral Unit Dose Services 2007-08-23 Not applicable US - Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Avandaryl Glimepiride (1 mg/1) + Rosiglitazone Maleate (4 mg/1) Tablet, film coated Oral Glaxosmithkline Inc 2011-05-24 2016-10-13 US Avandaryl Glimepiride (1 mg) + Rosiglitazone (4 mg) Tablet Oral Glaxosmithkline Inc 2006-05-04 2011-08-29 Canada Avandaryl Glimepiride (4 mg/1) + Rosiglitazone Maleate (8 mg/1) Tablet, film coated Oral Glaxosmithkline Inc 2011-05-24 2016-10-13 US Avandaryl Glimepiride (4 mg) + Rosiglitazone (4 mg) Tablet Oral Glaxosmithkline Inc 2006-05-04 2011-07-31 Canada Avandaryl Glimepiride (2 mg/1) + Rosiglitazone Maleate (8 mg/1) Tablet, film coated Oral Glaxosmithkline Inc 2011-05-24 2015-11-07 US Avandaryl Glimepiride (2 mg/1) + Rosiglitazone Maleate (4 mg/1) Tablet, film coated Oral Glaxosmithkline Inc 2011-05-24 2016-10-13 US Avandaryl Glimepiride (2 mg) + Rosiglitazone (4 mg) Tablet Oral Glaxosmithkline Inc 2006-05-04 2011-07-31 Canada Avandaryl Glimepiride (4 mg/1) + Rosiglitazone Maleate (4 mg/1) Tablet, film coated Oral Glaxosmithkline Inc 2011-05-24 2015-11-07 US Duetact Glimepiride (2 mg/1) + Pioglitazone Hydrochloride (30 mg/1) Tablet Oral Takeda 2006-07-28 Not applicable US Duetact Glimepiride (4 mg/1) + Pioglitazone Hydrochloride (30 mg/1) Tablet Oral Takeda 2006-07-28 Not applicable US 
- Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Avaglim Glimepiride (4 mg) + Rosiglitazone (4 mg) Tablet, film coated Oral Smith Kline Beecham 2006-06-27 2011-08-12 EU 
Avaglim Glimepiride (4 mg) + Rosiglitazone (4 mg) Tablet, film coated Oral Smith Kline Beecham 2006-06-27 2011-08-12 EU Avaglim Glimepiride (4 mg) + Rosiglitazone (8 mg) Tablet, film coated Oral Smith Kline Beecham 2006-06-27 2011-08-12 EU Avaglim Glimepiride (4 mg) + Rosiglitazone (4 mg) Tablet, film coated Oral Smith Kline Beecham 2006-06-27 2011-08-12 EU Avaglim Glimepiride (4 mg) + Rosiglitazone (8 mg) Tablet, film coated Oral Smith Kline Beecham 2006-06-27 2011-08-12 EU Avaglim Glimepiride (4 mg) + Rosiglitazone (8 mg) Tablet, film coated Oral Smith Kline Beecham 2006-06-27 2011-08-12 EU Avaglim Glimepiride (4 mg) + Rosiglitazone (4 mg) Tablet, film coated Oral Smith Kline Beecham 2006-06-27 2011-08-12 EU Avaglim Glimepiride (4 mg) + Rosiglitazone (8 mg) Tablet, film coated Oral Smith Kline Beecham 2006-06-27 2011-08-12 EU Avaglim Glimepiride (4 mg) + Rosiglitazone (8 mg) Tablet, film coated Oral Smith Kline Beecham 2006-06-27 2011-08-12 EU Avaglim Glimepiride (4 mg) + Rosiglitazone (4 mg) Tablet, film coated Oral Smith Kline Beecham 2006-06-27 2011-08-12 EU - International/Other Brands
- GLIMPID (Ranbaxy Laboratories) / GLIMY (Dr.Reddy's Labs)
- Categories
- Alimentary Tract and Metabolism
- Anti-Arrhythmia Agents
- Blood Glucose Lowering Agents
- Blood Glucose Lowering Drugs, Excl. Insulins
- Cardiovascular Agents
- Cytochrome P-450 CYP2C9 Substrates
- Drugs Used in Diabetes
- Hypoglycemia-Associated Agents
- Hypoglycemic Agents
- Immunologic Factors
- Immunosuppressive Agents
- Sulfones
- Sulfonylureas
- Sulfur Compounds
- Urea
- UNII
- 6KY687524K
- CAS number
- 93479-97-1
- Weight
- Average: 490.62
Monoisotopic: 490.224991385 - Chemical Formula
- C24H34N4O5S
- InChI Key
- WIGIZIANZCJQQY-RUCARUNLSA-N
- InChI
- InChI=1S/C24H34N4O5S/c1-4-21-17(3)15-28(22(21)29)24(31)25-14-13-18-7-11-20(12-8-18)34(32,33)27-23(30)26-19-9-5-16(2)6-10-19/h7-8,11-12,16,19H,4-6,9-10,13-15H2,1-3H3,(H,25,31)(H2,26,27,30)/t16-,19-
- IUPAC Name
- 3-ethyl-4-methyl-2-oxo-N-(2-{4-[({[(1r,4r)-4-methylcyclohexyl]-C-hydroxycarbonimidoyl}amino)sulfonyl]phenyl}ethyl)-2,5-dihydro-1H-pyrrole-1-carboximidic acid
- SMILES
- [H][[email protected]]1(C)CC[[email protected]@]([H])(CC1)N=C(O)NS(=O)(=O)C1=CC=C(CCN=C(O)N2CC(C)=C(CC)C2=O)C=C1
Pharmacology
- Indication
For concomitant use with insulin for the treatment of noninsulin-dependent (type 2) diabetes mellitus.
- Structured Indications
- Pharmacodynamics
Glimepiride, like glyburide and glipizide, is a "second-generation" sulfonylurea agents. Glimepiride is used with diet to lower blood glucose by increasing the secretion of insulin from pancreas and increasing the sensitivity of peripheral tissues to insulin.
- Mechanism of action
The mechanism of action of glimepiride in lowering blood glucose appears to be dependent on stimulating the release of insulin from functioning pancreatic beta cells, and increasing sensitivity of peripheral tissues to insulin. Glimepiride likely binds to ATP-sensitive potassium channel receptors on the pancreatic cell surface, reducing potassium conductance and causing depolarization of the membrane. Membrane depolarization stimulates calcium ion influx through voltage-sensitive calcium channels. This increase in intracellular calcium ion concentration induces the secretion of insulin.
Target Actions Organism AATP-sensitive inward rectifier potassium channel 11 inhibitorHuman AATP-sensitive inward rectifier potassium channel 1 inhibitorHuman AATP-binding cassette sub-family C member 8 inducerHuman - Absorption
Completely (100%) absorbed following oral administration.
- Volume of distribution
- 21.8 ± 13.9 L [Volunteers]
- 19.8 ± 12.7 L [Patients with Type 2 diabetes, Single Dose]
- 37.1 ± 18.2 L [Patients with Type 2 diabetes, Multiple Dose]
- Protein binding
Over 99.5% bound to plasma protein.
- Metabolism
Hepatic. Following either an intravenous or oral dose, glimepiride is completely metabolized by oxidative biotransformation to a major metabolite, cyclohexyl hydroxymethyl derivative (M1), via the hepatic cytochrome P450 II C9 subsystem. M1 is further metabolized to the carboxyl derivative (M2) by one or several cytosolic enzymes. M1, but not M2, possessed approximately one third of the pharmacologic activity of its parent in an animal model. However, whether the glucose-lowering effect of M1 is clinically significant is not clear.
- Route of elimination
- Not Available
- Half life
Approximately 5 hours following single dose.
- Clearance
- 52.1 +/- 16.0 mL/min [Normal subjects with single oral dose]
- 48.5 +/- 29.3 mL/min [Patients with Type 2 diabetes, with single oral dose]
- 52.7 +/- 40.3 mL/min [Patients with Type 2 diabetes, with multiple oral dose]
- 47.8 mL/min [healthy after intravenous (IV) dosing]
- Toxicity
Severe hypoglycemic reactions with coma, seizure, or other neurological impairment.
- Affected organisms
- Humans and other mammals
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
Interacting Gene/Enzyme Allele name Genotype(s) Defining Change(s) Type(s) Description Details Glucose-6-phosphate 1-dehydrogenase Villeurbanne Not Available 1000_1002delACC ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Torun Not Available 1006A->G ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Sunderland Not Available 105_107delCAT ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Iwatsuki Not Available 1081G->A ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Serres Not Available 1082C->T ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Tondela Not Available 1084_1101delCTGAACGAGCGCAAGGCC ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Loma Linda Not Available 1089C->A ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Aachen Not Available 1089C->G ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Tenri Not Available 1096A->G ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Montpellier Not Available 1132G>A ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Calvo Mackenna Not Available 1138A->G ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Riley Not Available 1139T->C ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Olomouc Not Available 1141T->C ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Tomah Not Available 1153T->C ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Lynwood Not Available 1154G->T ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Madrid Not Available 1155C->G ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Iowa, Walter Reed, Springfield Not Available 1156A->G ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Beverly Hills, Genova, Iwate, Niigata, Yamaguchi Not Available 1160G->A ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Hartford Not Available 1162A->G ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Praha Not Available 1166A->G ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Krakow Not Available 1175T>C ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Wisconsin Not Available 1177C->G ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Nashville, Anaheim, Portici Not Available 1178G->A ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Alhambra Not Available 1180G->C ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Bari Not Available 1187C->T ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Puerto Limon Not Available 1192G->A ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Covao do Lobo Not Available 1205C>A ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Clinic Not Available 1215G->A ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Utrecht Not Available 1225C->T ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Suwalki Not Available 1226C->G ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Riverside Not Available 1228G->T ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Japan, Shinagawa Not Available 1229G->A ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Kawasaki Not Available 1229G->C ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Munich Not Available 1231A->G ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Georgia Not Available 1284C->A ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Sumare Not Available 1292T->G ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Telti/Kobe Not Available 1318C->T ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Santiago de Cuba, Morioka Not Available 1339G->A ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Harima Not Available 1358T->A ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Figuera da Foz Not Available 1366G->C ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Amiens Not Available 1367A>T ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Bangkok Noi Not Available 1376G->T, 1502T->G ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Fukaya Not Available 1462G->A ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Campinas Not Available 1463G->T ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Buenos Aires Not Available 1465C>T ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Arakawa Not Available 1466C->T ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Brighton Not Available 1488_1490delGAA ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Kozukata Not Available 159G->C ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Amsterdam Not Available 180_182delTCT ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase No name Not Available 202G->A, 376A->G, 1264C>G ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Swansea Not Available 224T->C ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Urayasu Not Available 281_283delAGA ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Vancouver Not Available 317C->G544C->T592C->T ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Mt Sinai Not Available 376A->G, 1159C->T ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Plymouth Not Available 488G->A ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Volendam Not Available 514C->T ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Shinshu Not Available 527A->G ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Chikugo Not Available 535A->T ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Tsukui Not Available 561_563delCTC ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Pedoplis-Ckaro Not Available 573C>G ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Santiago Not Available 593G->C ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Minnesota, Marion, Gastonia, LeJeune Not Available 637G->T ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Cincinnati Not Available 637G->T, 1037A->T ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Harilaou Not Available 648T->G ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase North Dallas Not Available 683_685delACA ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Asahikawa Not Available 695G->A ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Durham Not Available 713A->G ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Stonybrook Not Available 724_729delGGCACT ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Wayne Not Available 769C->G ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Aveiro Not Available 806G->A ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Cleveland Corum Not Available 820G->A ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Lille Not Available 821A>T ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Bangkok Not Available 825G>C ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Sugao Not Available 826C->T ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase La Jolla Not Available 832T->C ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Wexham Not Available 833C->T ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Piotrkow Not Available 851T>C ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase West Virginia Not Available 910G->T ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Omiya Not Available 921G->C ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Nara Not Available 953_976delCCACCAAAGGGTACCTGGAC GACC ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Manhattan Not Available 962G->A ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Rehevot Not Available 964T->C ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Honiara Not Available 99A->G / 1360C->T ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Tokyo, Fukushima Not Available 1246G->A ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Chatham Not Available 1003G->A ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Fushan Not Available 1004C->A ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Partenope Not Available 1052G->T ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Ierapetra Not Available 1057C->T ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Anadia Not Available 1193A->G ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Abeno Not Available 1220A->C ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Surabaya Not Available 1291G->A ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Pawnee Not Available 1316G->C ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase S. Antioco Not Available 1342A->G ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Cassano Not Available 1347G->C ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Hermoupolis Not Available 1347G->C / 1360C->T ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Union,Maewo, Chinese-2, Kalo Not Available 1360C->T ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Andalus Not Available 1361G->A ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Cosenza Not Available 1376G->C ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Canton, Taiwan- Hakka, Gifu-like, Agrigento-like Not Available 1376G->T ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Flores Not Available 1387C->A ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Kaiping, Anant, Dhon, Sapporo-like, Wosera Not Available 1388G->A ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Kamogawa Not Available 169C->T ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Costanzo Not Available 179T>C ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Amazonia Not Available 185C->A ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Songklanagarind Not Available 196T->A ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Hechi Not Available 202G->A / 871G->A ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Namouru Not Available 208T->C ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Bao Loc Not Available 352T>C ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Crispim Not Available 375G->T, 379G->T383T->C384C>T ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Acrokorinthos Not Available 376A->G / 463C->G ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Santa Maria Not Available 376A->G / 542A->T ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Ananindeua Not Available 376A->G / 871G->A ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Vanua Lava Not Available 383T->C ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Valladolid Not Available 406C->T ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Belem Not Available 409C->T ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Liuzhou Not Available 442G->A ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Shenzen Not Available 473G>A ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Taipei ‚ÄúChinese- 3‚Äù Not Available 493A->G ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Toledo Not Available 496C>T ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Naone Not Available 497G->A ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Nankang Not Available 517T->C ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Miaoli Not Available 519C->G ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Mediterranean, Dallas, Panama‚ Sassari, Cagliari, Birmingham Not Available 563C->T ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Coimbra Shunde Not Available 592C->T ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Nilgiri Not Available 593G>A ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Radlowo Not Available 679C->T ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Roubaix Not Available 811G>C ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Haikou Not Available 835A->G ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Chinese-1 Not Available 835A->T ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Mizushima Not Available 848A>G ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Osaka Not Available 853C->T ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Viangchan, Jammu Not Available 871G->A ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Seoul Not Available 916G->A ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Ludhiana Not Available 929G->A ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Farroupilha Not Available 977C->A ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Chinese-5 Not Available 1024C->T ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Rignano Not Available 130G>A ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Orissa Not Available 131C->G ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase G6PDNice Not Available 1380G>C ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Kamiube, Keelung Not Available 1387C->T ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Neapolis Not Available 1400C->G ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Aures Not Available 143T->C ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Split Not Available 1442C->G ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Kambos Not Available 148C->T ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Palestrina Not Available 170G>A ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Metaponto Not Available 172G->A ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Musashino Not Available 185C->T ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Asahi Not Available 202G->A ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase A- (202), Ferrara I Not Available 202G->A / 376A->G ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Murcia Oristano Not Available 209A->G ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Ube Konan Not Available 241C->T ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Lagosanto Not Available 242G->A ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Guangzhou Not Available 274C->T ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Hammersmith Not Available 323T->A ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Sinnai Not Available 34G->T ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase A- (680) Not Available 376A->G / 680G->T ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase A- (968), Betica,Selma, Guantanamo Not Available 376A->G / 968T->C ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Salerno Pyrgos Not Available 383T>G ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Quing Yan Not Available 392G->T ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Lages Not Available 40G->A ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Ilesha Not Available 466G->A ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Mahidol Not Available 487G->A ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Malaga Not Available 542A->T ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Sibari Not Available 634A->G ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Mexico City Not Available 680G->A ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Nanning Not Available 703C->T ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Seattle, Lodi, Modena, Ferrara II, Athens-like Not Available 844G->C ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Bajo Maumere Not Available 844G->T ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Montalbano Not Available 854G->A ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Kalyan-Kerala, Jamnaga, Rohini Not Available 949G->A ADR Inferred Increased risk of hemolytic anemia. Details Glucose-6-phosphate 1-dehydrogenase Gaohe Not Available 95A->G ADR Inferred Increased risk of hemolytic anemia. Details
Interactions
- Drug Interactions
Drug Interaction Drug group 2,4-thiazolidinedione 2,4-thiazolidinedione may increase the hypoglycemic activities of Glimepiride. Investigational 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypoglycemic activities of Glimepiride. Experimental Abiraterone The metabolism of Glimepiride can be decreased when combined with Abiraterone. Approved Acarbose Acarbose may increase the hypoglycemic activities of Glimepiride. Approved, Investigational Acebutolol Acebutolol may increase the hypoglycemic activities of Glimepiride. Approved, Investigational Acenocoumarol Glimepiride may increase the anticoagulant activities of Acenocoumarol. Approved, Investigational Acetohexamide Acetohexamide may increase the hypoglycemic activities of Glimepiride. Approved, Investigational, Withdrawn Acetylsalicylic acid Acetylsalicylic acid may increase the hypoglycemic activities of Glimepiride. Approved, Vet Approved AICA ribonucleotide AICA ribonucleotide may increase the hypoglycemic activities of Glimepiride. Experimental, Investigational Alaproclate Alaproclate may increase the hypoglycemic activities of Glimepiride. Experimental Albiglutide Albiglutide may increase the hypoglycemic activities of Glimepiride. Approved Allicin Allicin may increase the hypoglycemic activities of Glimepiride. Investigational Alogliptin Alogliptin may increase the hypoglycemic activities of Glimepiride. Approved Aloxiprin Aloxiprin may increase the hypoglycemic activities of Glimepiride. Experimental Alprenolol Alprenolol may increase the hypoglycemic activities of Glimepiride. Approved, Withdrawn Aluminium clofibrate Aluminium clofibrate may increase the hypoglycemic activities of Glimepiride. Experimental Aminosalicylic Acid Aminosalicylic Acid may increase the hypoglycemic activities of Glimepiride. Approved Amiodarone The metabolism of Glimepiride can be decreased when combined with Amiodarone. Approved, Investigational Amphetamine Amphetamine may increase the hypoglycemic activities of Glimepiride. Approved, Illicit, Investigational Anthrax immune globulin human The risk or severity of adverse effects can be increased when Glimepiride is combined with Anthrax immune globulin human. Approved Apalutamide The serum concentration of Glimepiride can be decreased when it is combined with Apalutamide. Approved, Investigational Aprepitant The metabolism of Glimepiride can be increased when combined with Aprepitant. Approved, Investigational Aripiprazole The therapeutic efficacy of Glimepiride can be decreased when used in combination with Aripiprazole. Approved, Investigational Arotinolol Arotinolol may increase the hypoglycemic activities of Glimepiride. Investigational Arsenic trioxide The therapeutic efficacy of Glimepiride can be decreased when used in combination with Arsenic trioxide. Approved, Investigational Articaine The therapeutic efficacy of Glimepiride can be decreased when used in combination with Articaine. Approved Asenapine The therapeutic efficacy of Glimepiride can be decreased when used in combination with Asenapine. Approved Atazanavir The therapeutic efficacy of Glimepiride can be decreased when used in combination with Atazanavir. Approved, Investigational Atenolol Atenolol may increase the hypoglycemic activities of Glimepiride. Approved Atorvastatin Atorvastatin may increase the hypoglycemic activities of Glimepiride. Approved Bacillus calmette-guerin substrain connaught live antigen The risk or severity of adverse effects can be increased when Glimepiride is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved, Investigational Bacillus calmette-guerin substrain tice live antigen The risk or severity of adverse effects can be increased when Glimepiride is combined with Bacillus calmette-guerin substrain tice live antigen. Approved Balaglitazone Balaglitazone may increase the hypoglycemic activities of Glimepiride. Investigational Balsalazide Balsalazide may increase the hypoglycemic activities of Glimepiride. Approved, Investigational BCG vaccine The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Glimepiride. Investigational Befunolol Befunolol may increase the hypoglycemic activities of Glimepiride. Experimental Bempedoic acid Bempedoic acid may increase the hypoglycemic activities of Glimepiride. Investigational Bendroflumethiazide The therapeutic efficacy of Glimepiride can be decreased when used in combination with Bendroflumethiazide. Approved Benmoxin Benmoxin may increase the hypoglycemic activities of Glimepiride. Withdrawn Betamethasone The therapeutic efficacy of Glimepiride can be decreased when used in combination with Betamethasone. Approved, Vet Approved Betaxolol Betaxolol may increase the hypoglycemic activities of Glimepiride. Approved, Investigational Bevantolol Bevantolol may increase the hypoglycemic activities of Glimepiride. Approved Bezafibrate Bezafibrate may increase the hypoglycemic activities of Glimepiride. Approved, Investigational Bisoprolol Bisoprolol may increase the hypoglycemic activities of Glimepiride. Approved Bopindolol Bopindolol may increase the hypoglycemic activities of Glimepiride. Approved Brexpiprazole The therapeutic efficacy of Glimepiride can be decreased when used in combination with Brexpiprazole. Approved, Investigational Brofaromine Brofaromine may increase the hypoglycemic activities of Glimepiride. Experimental Bucindolol Bucindolol may increase the hypoglycemic activities of Glimepiride. Investigational Buformin Buformin may increase the hypoglycemic activities of Glimepiride. Investigational, Withdrawn Bufuralol Bufuralol may increase the hypoglycemic activities of Glimepiride. Experimental, Investigational Bumetanide The therapeutic efficacy of Glimepiride can be decreased when used in combination with Bumetanide. Approved Bupranolol Bupranolol may increase the hypoglycemic activities of Glimepiride. Approved Buserelin The therapeutic efficacy of Glimepiride can be decreased when used in combination with Buserelin. Approved, Investigational Canagliflozin Canagliflozin may increase the hypoglycemic activities of Glimepiride. Approved Capecitabine The metabolism of Glimepiride can be decreased when combined with Capecitabine. Approved, Investigational Carbamazepine The metabolism of Glimepiride can be increased when combined with Carbamazepine. Approved, Investigational Carbaspirin calcium Carbaspirin calcium may increase the hypoglycemic activities of Glimepiride. Experimental, Investigational Carbocisteine The risk or severity of adverse effects can be increased when Glimepiride is combined with Carbocisteine. Approved, Investigational Carbutamide Carbutamide may increase the hypoglycemic activities of Glimepiride. Experimental Caroxazone Caroxazone may increase the hypoglycemic activities of Glimepiride. Withdrawn Carteolol Carteolol may increase the hypoglycemic activities of Glimepiride. Approved Carvedilol Carvedilol may increase the hypoglycemic activities of Glimepiride. Approved, Investigational Castanospermine Castanospermine may increase the hypoglycemic activities of Glimepiride. Experimental Celiprolol Celiprolol may increase the hypoglycemic activities of Glimepiride. Approved, Investigational Ceritinib The serum concentration of Glimepiride can be increased when it is combined with Ceritinib. Approved Chloramphenicol The metabolism of Glimepiride can be decreased when combined with Chloramphenicol. Approved, Vet Approved Chlorothiazide The therapeutic efficacy of Glimepiride can be decreased when used in combination with Chlorothiazide. Approved, Vet Approved Chlorpropamide Glimepiride may increase the hypoglycemic activities of Chlorpropamide. Approved, Investigational Chlorthalidone The therapeutic efficacy of Glimepiride can be decreased when used in combination with Chlorthalidone. Approved Cholecalciferol The metabolism of Glimepiride can be decreased when combined with Cholecalciferol. Approved, Nutraceutical Ciglitazone Ciglitazone may increase the hypoglycemic activities of Glimepiride. Experimental Cimetidine The serum concentration of Glimepiride can be increased when it is combined with Cimetidine. Approved, Investigational Cinoxacin Cinoxacin may increase the hypoglycemic activities of Glimepiride. Approved, Investigational, Withdrawn Ciprofibrate Ciprofibrate may increase the hypoglycemic activities of Glimepiride. Approved, Investigational Citalopram Citalopram may increase the hypoglycemic activities of Glimepiride. Approved Clofibrate Clofibrate may increase the hypoglycemic activities of Glimepiride. Approved, Investigational Clofibride Clofibride may increase the hypoglycemic activities of Glimepiride. Experimental Cloranolol Cloranolol may increase the hypoglycemic activities of Glimepiride. Experimental Clorindione Glimepiride may increase the anticoagulant activities of Clorindione. Experimental Clostridium tetani toxoid antigen (formaldehyde inactivated) The risk or severity of adverse effects can be increased when Glimepiride is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated). Approved Clotrimazole The metabolism of Glimepiride can be decreased when combined with Clotrimazole. Approved, Vet Approved Clozapine The therapeutic efficacy of Glimepiride can be decreased when used in combination with Clozapine. Approved Colesevelam The serum concentration of Glimepiride can be decreased when it is combined with Colesevelam. Approved Corticotropin The therapeutic efficacy of Glimepiride can be decreased when used in combination with Corticotropin. Approved, Investigational, Vet Approved Cortisone acetate The therapeutic efficacy of Glimepiride can be decreased when used in combination with Cortisone acetate. Approved, Investigational Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) The risk or severity of adverse effects can be increased when Glimepiride is combined with Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated). Approved Crisaborole The metabolism of Glimepiride can be decreased when combined with Crisaborole. Approved, Investigational Cyclopenthiazide The therapeutic efficacy of Glimepiride can be decreased when used in combination with Cyclopenthiazide. Experimental Cyclosporine The metabolism of Glimepiride can be decreased when combined with Cyclosporine. Approved, Investigational, Vet Approved Cyproterone acetate The therapeutic efficacy of Glimepiride can be decreased when used in combination with Cyproterone acetate. Approved, Investigational Dabrafenib The serum concentration of Glimepiride can be decreased when it is combined with Dabrafenib. Approved, Investigational Danazol The therapeutic efficacy of Glimepiride can be decreased when used in combination with Danazol. Approved Dapoxetine Dapoxetine may increase the hypoglycemic activities of Glimepiride. Investigational Darunavir The therapeutic efficacy of Glimepiride can be decreased when used in combination with Darunavir. Approved Delavirdine The metabolism of Glimepiride can be decreased when combined with Delavirdine. Approved Denosumab The risk or severity of adverse effects can be increased when Denosumab is combined with Glimepiride. Approved Deoxyspergualin Deoxyspergualin may increase the hypoglycemic activities of Glimepiride. Investigational Dersalazine Dersalazine may increase the hypoglycemic activities of Glimepiride. Investigational Desogestrel The therapeutic efficacy of Glimepiride can be decreased when used in combination with Desogestrel. Approved Desvenlafaxine Desvenlafaxine may increase the hypoglycemic activities of Glimepiride. Approved, Investigational Dexamethasone The therapeutic efficacy of Glimepiride can be decreased when used in combination with Dexamethasone. Approved, Investigational, Vet Approved Diazoxide The therapeutic efficacy of Glimepiride can be decreased when used in combination with Diazoxide. Approved Dicoumarol Glimepiride may increase the anticoagulant activities of Dicoumarol. Approved Dienogest The therapeutic efficacy of Glimepiride can be decreased when used in combination with Dienogest. Approved Diflunisal Diflunisal may increase the hypoglycemic activities of Glimepiride. Approved, Investigational Diphenadione Glimepiride may increase the anticoagulant activities of Diphenadione. Experimental Disopyramide Glimepiride may increase the hypoglycemic activities of Disopyramide. Approved Dosulepin The metabolism of Glimepiride can be decreased when combined with Dosulepin. Approved Drospirenone The therapeutic efficacy of Glimepiride can be decreased when used in combination with Drospirenone. Approved Dulaglutide Dulaglutide may increase the hypoglycemic activities of Glimepiride. Approved, Investigational Duloxetine Duloxetine may increase the hypoglycemic activities of Glimepiride. Approved Efavirenz The metabolism of Glimepiride can be decreased when combined with Efavirenz. Approved, Investigational Empagliflozin Empagliflozin may increase the hypoglycemic activities of Glimepiride. Approved Enoxacin Enoxacin may increase the hypoglycemic activities of Glimepiride. Approved, Investigational Epanolol Epanolol may increase the hypoglycemic activities of Glimepiride. Experimental Epinephrine The therapeutic efficacy of Glimepiride can be decreased when used in combination with Epinephrine. Approved, Vet Approved Epitizide The therapeutic efficacy of Glimepiride can be decreased when used in combination with Epitizide. Experimental Ertugliflozin Ertugliflozin may increase the hypoglycemic activities of Glimepiride. Approved, Investigational Escitalopram Escitalopram may increase the hypoglycemic activities of Glimepiride. Approved, Investigational Esmolol Esmolol may increase the hypoglycemic activities of Glimepiride. Approved Estradiol The therapeutic efficacy of Glimepiride can be decreased when used in combination with Estradiol. Approved, Investigational, Vet Approved Estrone sulfate The therapeutic efficacy of Glimepiride can be decreased when used in combination with Estrone sulfate. Approved Etacrynic acid The therapeutic efficacy of Glimepiride can be decreased when used in combination with Etacrynic acid. Approved, Investigational Ethanol The risk or severity of adverse effects can be increased when Glimepiride is combined with Ethanol. Approved Ethinyl Estradiol The therapeutic efficacy of Glimepiride can be decreased when used in combination with Ethinyl Estradiol. Approved Ethyl biscoumacetate Glimepiride may increase the anticoagulant activities of Ethyl biscoumacetate. Withdrawn Ethynodiol diacetate The therapeutic efficacy of Glimepiride can be decreased when used in combination with Ethynodiol diacetate. Approved Etofibrate Etofibrate may increase the hypoglycemic activities of Glimepiride. Approved Etonogestrel The therapeutic efficacy of Glimepiride can be decreased when used in combination with Etonogestrel. Approved, Investigational Etoperidone Etoperidone may increase the hypoglycemic activities of Glimepiride. Withdrawn Etravirine The metabolism of Glimepiride can be decreased when combined with Etravirine. Approved Everolimus The therapeutic efficacy of Glimepiride can be decreased when used in combination with Everolimus. Approved Exenatide Exenatide may increase the hypoglycemic activities of Glimepiride. Approved, Investigational Fenofibrate Fenofibrate may increase the hypoglycemic activities of Glimepiride. Approved Fenofibric acid Fenofibric acid may increase the hypoglycemic activities of Glimepiride. Approved Fingolimod Glimepiride may increase the immunosuppressive activities of Fingolimod. Approved, Investigational Fleroxacin Fleroxacin may increase the hypoglycemic activities of Glimepiride. Approved Floxuridine The metabolism of Glimepiride can be decreased when combined with Floxuridine. Approved Fluconazole The serum concentration of Glimepiride can be increased when it is combined with Fluconazole. Approved, Investigational Fludrocortisone The therapeutic efficacy of Glimepiride can be decreased when used in combination with Fludrocortisone. Approved, Investigational Fluindione Glimepiride may increase the anticoagulant activities of Fluindione. Approved, Investigational Flumequine Flumequine may increase the hypoglycemic activities of Glimepiride. Withdrawn Fluorouracil The metabolism of Glimepiride can be decreased when combined with Fluorouracil. Approved Fluoxetine Fluoxetine may increase the hypoglycemic activities of Glimepiride. Approved, Vet Approved Fluoxymesterone Fluoxymesterone may increase the hypoglycemic activities of Glimepiride. Approved, Illicit Fluvastatin The metabolism of Glimepiride can be decreased when combined with Fluvastatin. Approved Fluvoxamine The metabolism of Glimepiride can be decreased when combined with Fluvoxamine. Approved, Investigational Fosamprenavir The therapeutic efficacy of Glimepiride can be decreased when used in combination with Fosamprenavir. Approved Fosphenytoin The metabolism of Glimepiride can be increased when combined with Fosphenytoin. Approved, Investigational Furazolidone Furazolidone may increase the hypoglycemic activities of Glimepiride. Approved, Investigational, Vet Approved Furosemide The therapeutic efficacy of Glimepiride can be decreased when used in combination with Furosemide. Approved, Vet Approved G17DT The risk or severity of adverse effects can be increased when Glimepiride is combined with G17DT. Investigational Garenoxacin Garenoxacin may increase the hypoglycemic activities of Glimepiride. Investigational Gatifloxacin Gatifloxacin may increase the hypoglycemic activities of Glimepiride. Approved, Investigational Gemfibrozil The metabolism of Glimepiride can be decreased when combined with Gemfibrozil. Approved Gemifloxacin Gemifloxacin may increase the hypoglycemic activities of Glimepiride. Approved, Investigational GI-5005 The risk or severity of adverse effects can be increased when Glimepiride is combined with GI-5005. Investigational Glibornuride Glibornuride may increase the hypoglycemic activities of Glimepiride. Investigational, Withdrawn Gliclazide Glimepiride may increase the hypoglycemic activities of Gliclazide. Approved Glipizide Glimepiride may increase the hypoglycemic activities of Glipizide. Approved, Investigational Gliquidone Gliquidone may increase the hypoglycemic activities of Glimepiride. Approved, Investigational GLPG-0492 GLPG-0492 may increase the hypoglycemic activities of Glimepiride. Investigational Glyburide Glimepiride may increase the hypoglycemic activities of Glyburide. Approved Goserelin The therapeutic efficacy of Glimepiride can be decreased when used in combination with Goserelin. Approved Grepafloxacin Grepafloxacin may increase the hypoglycemic activities of Glimepiride. Approved, Investigational, Withdrawn Guacetisal Guacetisal may increase the hypoglycemic activities of Glimepiride. Experimental Gusperimus Gusperimus may increase the hypoglycemic activities of Glimepiride. Investigational Harmaline Harmaline may increase the hypoglycemic activities of Glimepiride. Experimental Hemoglobin crosfumaril Hemoglobin crosfumaril may increase the hypoglycemic activities of Glimepiride. Experimental Hepatitis A Vaccine The risk or severity of adverse effects can be increased when Glimepiride is combined with Hepatitis A Vaccine. Approved Hepatitis B Vaccine (Recombinant) The risk or severity of adverse effects can be increased when Glimepiride is combined with Hepatitis B Vaccine (Recombinant). Approved, Withdrawn Histrelin The therapeutic efficacy of Glimepiride can be decreased when used in combination with Histrelin. Approved Human rabies virus immune globulin The risk or severity of adverse effects can be increased when Glimepiride is combined with Human rabies virus immune globulin. Approved Hydracarbazine Hydracarbazine may increase the hypoglycemic activities of Glimepiride. Experimental Hydrochlorothiazide The therapeutic efficacy of Glimepiride can be decreased when used in combination with Hydrochlorothiazide. Approved, Vet Approved Hydrocortisone The therapeutic efficacy of Glimepiride can be decreased when used in combination with Hydrocortisone. Approved, Vet Approved Hydroflumethiazide The therapeutic efficacy of Glimepiride can be decreased when used in combination with Hydroflumethiazide. Approved, Investigational Hydroxyprogesterone caproate The therapeutic efficacy of Glimepiride can be decreased when used in combination with Hydroxyprogesterone caproate. Approved, Investigational Iloperidone The therapeutic efficacy of Glimepiride can be decreased when used in combination with Iloperidone. Approved Indalpine Indalpine may increase the hypoglycemic activities of Glimepiride. Investigational, Withdrawn Indapamide The therapeutic efficacy of Glimepiride can be decreased when used in combination with Indapamide. Approved Indenolol Indenolol may increase the hypoglycemic activities of Glimepiride. Withdrawn Indinavir The metabolism of Glimepiride can be decreased when combined with Indinavir. Approved INGN 201 The risk or severity of adverse effects can be increased when Glimepiride is combined with INGN 201. Investigational INGN 225 The risk or severity of adverse effects can be increased when Glimepiride is combined with INGN 225. Investigational Insulin Aspart Glimepiride may increase the hypoglycemic activities of Insulin Aspart. Approved Insulin Detemir Glimepiride may increase the hypoglycemic activities of Insulin Detemir. Approved Insulin Glargine Insulin Glargine may increase the hypoglycemic activities of Glimepiride. Approved Insulin Glulisine Glimepiride may increase the hypoglycemic activities of Insulin Glulisine. Approved Insulin Human Insulin Human may increase the hypoglycemic activities of Glimepiride. Approved, Investigational Insulin Lispro Insulin Lispro may increase the hypoglycemic activities of Glimepiride. Approved Insulin Pork Insulin Pork may increase the hypoglycemic activities of Glimepiride. Approved Iproclozide Iproclozide may increase the hypoglycemic activities of Glimepiride. Withdrawn Iproniazid Iproniazid may increase the hypoglycemic activities of Glimepiride. Withdrawn Irbesartan The metabolism of Glimepiride can be decreased when combined with Irbesartan. Approved, Investigational Isocarboxazid Isocarboxazid may increase the hypoglycemic activities of Glimepiride. Approved Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) The risk or severity of adverse effects can be increased when Glimepiride is combined with Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated). Approved Ketoconazole The metabolism of Glimepiride can be decreased when combined with Ketoconazole. Approved, Investigational Labetalol Labetalol may increase the hypoglycemic activities of Glimepiride. Approved Landiolol Landiolol may increase the hypoglycemic activities of Glimepiride. Investigational Lanreotide Glimepiride may increase the hypoglycemic activities of Lanreotide. Approved Leflunomide The risk or severity of adverse effects can be increased when Glimepiride is combined with Leflunomide. Approved, Investigational Leuprolide The therapeutic efficacy of Glimepiride can be decreased when used in combination with Leuprolide. Approved, Investigational Levobunolol Levobunolol may increase the hypoglycemic activities of Glimepiride. Approved Levofloxacin Levofloxacin may increase the hypoglycemic activities of Glimepiride. Approved, Investigational Levomilnacipran Levomilnacipran may increase the hypoglycemic activities of Glimepiride. Approved, Investigational Levonorgestrel The therapeutic efficacy of Glimepiride can be decreased when used in combination with Levonorgestrel. Approved, Investigational Linagliptin Linagliptin may increase the hypoglycemic activities of Glimepiride. Approved Lipoic Acid Lipoic Acid may increase the hypoglycemic activities of Glimepiride. Approved, Investigational, Nutraceutical Liraglutide Liraglutide may increase the hypoglycemic activities of Glimepiride. Approved Lobeglitazone The metabolism of Glimepiride can be decreased when combined with Lobeglitazone. Approved, Investigational Lopinavir The therapeutic efficacy of Glimepiride can be decreased when used in combination with Lopinavir. Approved Losartan The metabolism of Glimepiride can be decreased when combined with Losartan. Approved Lovastatin The metabolism of Glimepiride can be decreased when combined with Lovastatin. Approved, Investigational Lumacaftor The serum concentration of Glimepiride can be decreased when it is combined with Lumacaftor. Approved Lurasidone The therapeutic efficacy of Glimepiride can be decreased when used in combination with Lurasidone. Approved, Investigational Manidipine The metabolism of Glimepiride can be decreased when combined with Manidipine. Approved, Investigational Mebanazine Mebanazine may increase the hypoglycemic activities of Glimepiride. Withdrawn Mecasermin Glimepiride may increase the hypoglycemic activities of Mecasermin. Approved, Investigational Medrogestone The serum concentration of Glimepiride can be decreased when it is combined with Medrogestone. Approved Medroxyprogesterone acetate The therapeutic efficacy of Glimepiride can be decreased when used in combination with Medroxyprogesterone acetate. Approved, Investigational Megestrol acetate The therapeutic efficacy of Glimepiride can be decreased when used in combination with Megestrol acetate. Approved, Investigational, Vet Approved Mepindolol Mepindolol may increase the hypoglycemic activities of Glimepiride. Experimental Mesalazine Mesalazine may increase the hypoglycemic activities of Glimepiride. Approved Mesterolone Mesterolone may increase the hypoglycemic activities of Glimepiride. Experimental Mestranol The therapeutic efficacy of Glimepiride can be decreased when used in combination with Mestranol. Approved Metformin Metformin may increase the hypoglycemic activities of Glimepiride. Approved Methotrimeprazine The therapeutic efficacy of Glimepiride can be decreased when used in combination with Methotrimeprazine. Approved, Investigational Methyclothiazide The therapeutic efficacy of Glimepiride can be decreased when used in combination with Methyclothiazide. Approved Methyl salicylate Methyl salicylate may increase the hypoglycemic activities of Glimepiride. Approved, Vet Approved Methylene blue Methylene blue may increase the hypoglycemic activities of Glimepiride. Approved, Investigational Methylprednisolone The therapeutic efficacy of Glimepiride can be decreased when used in combination with Methylprednisolone. Approved, Vet Approved Methyltestosterone Methyltestosterone may increase the hypoglycemic activities of Glimepiride. Approved Metipranolol Metipranolol may increase the hypoglycemic activities of Glimepiride. Approved Metolazone The therapeutic efficacy of Glimepiride can be decreased when used in combination with Metolazone. Approved Metoprolol Metoprolol may increase the hypoglycemic activities of Glimepiride. Approved, Investigational Metreleptin Metreleptin may increase the hypoglycemic activities of Glimepiride. Approved Miconazole Miconazole may increase the hypoglycemic activities of Glimepiride. Approved, Investigational, Vet Approved Midostaurin The metabolism of Glimepiride can be decreased when combined with Midostaurin. Approved, Investigational Mifepristone The serum concentration of Glimepiride can be increased when it is combined with Mifepristone. Approved, Investigational Miglitol Miglitol may increase the hypoglycemic activities of Glimepiride. Approved Miglustat Miglustat may increase the hypoglycemic activities of Glimepiride. Approved Milnacipran Milnacipran may increase the hypoglycemic activities of Glimepiride. Approved, Investigational Minaprine Minaprine may increase the hypoglycemic activities of Glimepiride. Approved Mitiglinide Mitiglinide may increase the hypoglycemic activities of Glimepiride. Approved, Investigational Moclobemide Moclobemide may increase the hypoglycemic activities of Glimepiride. Approved, Investigational Nadolol Nadolol may increase the hypoglycemic activities of Glimepiride. Approved Nalidixic Acid Nalidixic Acid may increase the hypoglycemic activities of Glimepiride. Approved, Investigational Nandrolone Nandrolone may increase the hypoglycemic activities of Glimepiride. Experimental, Investigational Nandrolone decanoate Nandrolone decanoate may increase the hypoglycemic activities of Glimepiride. Approved, Illicit Natalizumab The risk or severity of adverse effects can be increased when Glimepiride is combined with Natalizumab. Approved, Investigational Nateglinide Glimepiride may increase the hypoglycemic activities of Nateglinide. Approved, Investigational Nebivolol Nebivolol may increase the hypoglycemic activities of Glimepiride. Approved, Investigational Nefazodone Nefazodone may increase the hypoglycemic activities of Glimepiride. Approved, Withdrawn Nelfinavir The therapeutic efficacy of Glimepiride can be decreased when used in combination with Nelfinavir. Approved Nemonoxacin Nemonoxacin may increase the hypoglycemic activities of Glimepiride. Investigational Niacin The therapeutic efficacy of Glimepiride can be decreased when used in combination with Niacin. Approved, Investigational, Nutraceutical Nialamide Nialamide may increase the hypoglycemic activities of Glimepiride. Withdrawn Nicardipine The metabolism of Glimepiride can be decreased when combined with Nicardipine. Approved, Investigational Nilotinib The therapeutic efficacy of Glimepiride can be decreased when used in combination with Nilotinib. Approved, Investigational Nitroaspirin Nitroaspirin may increase the hypoglycemic activities of Glimepiride. Investigational Norethisterone The therapeutic efficacy of Glimepiride can be decreased when used in combination with Norethisterone. Approved Norfloxacin Norfloxacin may increase the hypoglycemic activities of Glimepiride. Approved Norgestimate The therapeutic efficacy of Glimepiride can be decreased when used in combination with Norgestimate. Approved, Investigational Ocrelizumab Ocrelizumab may increase the immunosuppressive activities of Glimepiride. Approved, Investigational Octamoxin Octamoxin may increase the hypoglycemic activities of Glimepiride. Withdrawn Octreotide Octreotide may increase the hypoglycemic activities of Glimepiride. Approved, Investigational Olanzapine The therapeutic efficacy of Glimepiride can be decreased when used in combination with Olanzapine. Approved, Investigational Olsalazine Olsalazine may increase the hypoglycemic activities of Glimepiride. Approved Omeprazole The metabolism of Glimepiride can be decreased when combined with Omeprazole. Approved, Investigational, Vet Approved Oxandrolone Oxandrolone may increase the hypoglycemic activities of Glimepiride. Approved, Investigational Oxolinic acid Oxolinic acid may increase the hypoglycemic activities of Glimepiride. Experimental Oxprenolol Oxprenolol may increase the hypoglycemic activities of Glimepiride. Approved Oxymetholone Oxymetholone may increase the hypoglycemic activities of Glimepiride. Approved, Illicit Paliperidone The therapeutic efficacy of Glimepiride can be decreased when used in combination with Paliperidone. Approved Pargyline Pargyline may increase the hypoglycemic activities of Glimepiride. Approved Paroxetine Paroxetine may increase the hypoglycemic activities of Glimepiride. Approved, Investigational Pasireotide Glimepiride may increase the hypoglycemic activities of Pasireotide. Approved Pazufloxacin Pazufloxacin may increase the hypoglycemic activities of Glimepiride. Investigational Pefloxacin Pefloxacin may increase the hypoglycemic activities of Glimepiride. Approved Pegvisomant Pegvisomant may increase the hypoglycemic activities of Glimepiride. Approved Penbutolol Penbutolol may increase the hypoglycemic activities of Glimepiride. Approved, Investigational Pentamidine Glimepiride may increase the hypoglycemic activities of Pentamidine. Approved, Investigational Phenelzine Phenelzine may increase the hypoglycemic activities of Glimepiride. Approved Phenformin Phenformin may increase the hypoglycemic activities of Glimepiride. Approved, Investigational, Withdrawn Phenindione Glimepiride may increase the anticoagulant activities of Phenindione. Approved, Investigational Pheniprazine Pheniprazine may increase the hypoglycemic activities of Glimepiride. Withdrawn Phenobarbital The metabolism of Glimepiride can be increased when combined with Phenobarbital. Approved, Investigational Phenoxypropazine Phenoxypropazine may increase the hypoglycemic activities of Glimepiride. Withdrawn Phenprocoumon Glimepiride may increase the anticoagulant activities of Phenprocoumon. Approved, Investigational Phenyl aminosalicylate Phenyl aminosalicylate may increase the hypoglycemic activities of Glimepiride. Approved Phenytoin The metabolism of Glimepiride can be increased when combined with Phenytoin. Approved, Vet Approved Pimecrolimus The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Glimepiride. Approved, Investigational Pindolol Pindolol may increase the hypoglycemic activities of Glimepiride. Approved, Investigational Pioglitazone Pioglitazone may increase the hypoglycemic activities of Glimepiride. Approved, Investigational Pipemidic acid Pipemidic acid may increase the hypoglycemic activities of Glimepiride. Experimental Piperazine The therapeutic efficacy of Glimepiride can be decreased when used in combination with Piperazine. Approved, Vet Approved Pipotiazine The therapeutic efficacy of Glimepiride can be decreased when used in combination with Pipotiazine. Approved, Investigational Pirlindole Pirlindole may increase the hypoglycemic activities of Glimepiride. Approved Piromidic acid Piromidic acid may increase the hypoglycemic activities of Glimepiride. Experimental Pivhydrazine Pivhydrazine may increase the hypoglycemic activities of Glimepiride. Withdrawn Platelet Activating Factor Platelet Activating Factor may increase the hypoglycemic activities of Glimepiride. Experimental Polythiazide The therapeutic efficacy of Glimepiride can be decreased when used in combination with Polythiazide. Approved Practolol Practolol may increase the hypoglycemic activities of Glimepiride. Approved Pramlintide Pramlintide may increase the hypoglycemic activities of Glimepiride. Approved, Investigational Prednisolone The therapeutic efficacy of Glimepiride can be decreased when used in combination with Prednisolone. Approved, Vet Approved Prednisone The therapeutic efficacy of Glimepiride can be decreased when used in combination with Prednisone. Approved, Vet Approved Pregabalin The risk or severity of heart failure can be increased when Pregabalin is combined with Glimepiride. Approved, Illicit, Investigational Primidone The metabolism of Glimepiride can be increased when combined with Primidone. Approved, Vet Approved Probenecid The protein binding of Glimepiride can be decreased when combined with Probenecid. Approved, Investigational Procarbazine Procarbazine may increase the hypoglycemic activities of Glimepiride. Approved, Investigational Progesterone The therapeutic efficacy of Glimepiride can be decreased when used in combination with Progesterone. Approved, Vet Approved Propranolol Propranolol may increase the hypoglycemic activities of Glimepiride. Approved, Investigational Prulifloxacin Prulifloxacin may increase the hypoglycemic activities of Glimepiride. Investigational Pyrimethamine The metabolism of Glimepiride can be decreased when combined with Pyrimethamine. Approved, Investigational, Vet Approved Quetiapine The therapeutic efficacy of Glimepiride can be decreased when used in combination with Quetiapine. Approved Quinethazone The therapeutic efficacy of Glimepiride can be decreased when used in combination with Quinethazone. Approved Quinine The metabolism of Glimepiride can be decreased when combined with Quinine. Approved Rabies virus inactivated antigen, A The risk or severity of adverse effects can be increased when Glimepiride is combined with Rabies virus inactivated antigen, A. Approved, Investigational Rabies virus inactivated antigen, A The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Glimepiride. Approved, Investigational Ranitidine The serum concentration of Glimepiride can be increased when it is combined with Ranitidine. Approved Rasagiline Rasagiline may increase the hypoglycemic activities of Glimepiride. Approved Repaglinide Glimepiride may increase the hypoglycemic activities of Repaglinide. Approved, Investigational Rifampicin The serum concentration of Glimepiride can be decreased when it is combined with Rifampicin. Approved Rifapentine The metabolism of Glimepiride can be increased when combined with Rifapentine. Approved, Investigational Rindopepimut The risk or severity of adverse effects can be increased when Glimepiride is combined with Rindopepimut. Investigational Risperidone The therapeutic efficacy of Glimepiride can be decreased when used in combination with Risperidone. Approved, Investigational Ritonavir The therapeutic efficacy of Glimepiride can be decreased when used in combination with Ritonavir. Approved, Investigational Roflumilast Roflumilast may increase the immunosuppressive activities of Glimepiride. Approved Ronifibrate Ronifibrate may increase the hypoglycemic activities of Glimepiride. Experimental Rosiglitazone Rosiglitazone may increase the hypoglycemic activities of Glimepiride. Approved, Investigational Rosoxacin Rosoxacin may increase the hypoglycemic activities of Glimepiride. Approved, Investigational Rotavirus Vaccine The risk or severity of adverse effects can be increased when Glimepiride is combined with Rotavirus Vaccine. Approved Rubella virus vaccine The risk or severity of adverse effects can be increased when Glimepiride is combined with Rubella virus vaccine. Approved, Investigational Rucaparib The metabolism of Glimepiride can be decreased when combined with Rucaparib. Approved, Investigational Rufloxacin Rufloxacin may increase the hypoglycemic activities of Glimepiride. Experimental Safrazine Safrazine may increase the hypoglycemic activities of Glimepiride. Withdrawn Salicylic acid Salicylic acid may increase the hypoglycemic activities of Glimepiride. Approved, Investigational, Vet Approved Salmonella typhi ty2 vi polysaccharide antigen The risk or severity of adverse effects can be increased when Glimepiride is combined with Salmonella typhi ty2 vi polysaccharide antigen. Approved Salmonella typhi ty21a live antigen The risk or severity of adverse effects can be increased when Glimepiride is combined with Salmonella typhi ty21a live antigen. Approved Saquinavir The therapeutic efficacy of Glimepiride can be decreased when used in combination with Saquinavir. Approved, Investigational Saxagliptin Saxagliptin may increase the hypoglycemic activities of Glimepiride. Approved Secobarbital The metabolism of Glimepiride can be increased when combined with Secobarbital. Approved, Vet Approved Selegiline Selegiline may increase the hypoglycemic activities of Glimepiride. Approved, Investigational, Vet Approved Sertraline Sertraline may increase the hypoglycemic activities of Glimepiride. Approved Sildenafil The metabolism of Glimepiride can be decreased when combined with Sildenafil. Approved, Investigational Simfibrate Simfibrate may increase the hypoglycemic activities of Glimepiride. Experimental Sipuleucel-T The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Glimepiride. Approved, Investigational Sirolimus The therapeutic efficacy of Glimepiride can be decreased when used in combination with Sirolimus. Approved, Investigational Sitafloxacin Sitafloxacin may increase the hypoglycemic activities of Glimepiride. Experimental, Investigational Sitagliptin Sitagliptin may increase the hypoglycemic activities of Glimepiride. Approved, Investigational Sorafenib The metabolism of Glimepiride can be decreased when combined with Sorafenib. Approved, Investigational Sotagliflozin Sotagliflozin may increase the hypoglycemic activities of Glimepiride. Investigational Sotalol Sotalol may increase the hypoglycemic activities of Glimepiride. Approved Sparfloxacin Sparfloxacin may increase the hypoglycemic activities of Glimepiride. Approved, Investigational SRP 299 The risk or severity of adverse effects can be increased when Glimepiride is combined with SRP 299. Investigational Stanolone Stanolone may increase the hypoglycemic activities of Glimepiride. Illicit, Investigational Stanozolol Stanozolol may increase the hypoglycemic activities of Glimepiride. Approved, Vet Approved Sulfadiazine The metabolism of Glimepiride can be decreased when combined with Sulfadiazine. Approved, Investigational, Vet Approved Sulfamethoxazole The metabolism of Glimepiride can be decreased when combined with Sulfamethoxazole. Approved Sulfisoxazole The metabolism of Glimepiride can be decreased when combined with Sulfisoxazole. Approved, Vet Approved Sulodexide Sulodexide may increase the hypoglycemic activities of Glimepiride. Approved, Investigational Sunitinib Glimepiride may increase the hypoglycemic activities of Sunitinib. Approved, Investigational Tacrolimus Tacrolimus may increase the immunosuppressive activities of Glimepiride. Approved, Investigational Talinolol Talinolol may increase the hypoglycemic activities of Glimepiride. Investigational Tecemotide The risk or severity of adverse effects can be increased when Glimepiride is combined with Tecemotide. Investigational Temafloxacin Temafloxacin may increase the hypoglycemic activities of Glimepiride. Withdrawn Temsirolimus The therapeutic efficacy of Glimepiride can be decreased when used in combination with Temsirolimus. Approved Tertatolol Tertatolol may increase the hypoglycemic activities of Glimepiride. Experimental Testosterone Testosterone may increase the hypoglycemic activities of Glimepiride. Approved, Investigational Testosterone cypionate Testosterone cypionate may increase the hypoglycemic activities of Glimepiride. Approved Testosterone enanthate Testosterone enanthate may increase the hypoglycemic activities of Glimepiride. Approved Testosterone propionate Testosterone propionate may increase the hypoglycemic activities of Glimepiride. Approved, Investigational, Vet Approved, Withdrawn Testosterone undecanoate Testosterone undecanoate may increase the hypoglycemic activities of Glimepiride. Approved, Investigational TG4010 The risk or severity of adverse effects can be increased when Glimepiride is combined with TG4010. Investigational Ticagrelor The metabolism of Glimepiride can be decreased when combined with Ticagrelor. Approved Ticlopidine The metabolism of Glimepiride can be decreased when combined with Ticlopidine. Approved Timolol Timolol may increase the hypoglycemic activities of Glimepiride. Approved Tioclomarol Glimepiride may increase the anticoagulant activities of Tioclomarol. Experimental Tipranavir The therapeutic efficacy of Glimepiride can be decreased when used in combination with Tipranavir. Approved, Investigational Tofacitinib Glimepiride may increase the immunosuppressive activities of Tofacitinib. Approved, Investigational Tolazamide Glimepiride may increase the hypoglycemic activities of Tolazamide. Approved, Investigational Tolbutamide The metabolism of Glimepiride can be decreased when combined with Tolbutamide. Approved, Investigational Toloxatone Toloxatone may increase the hypoglycemic activities of Glimepiride. Approved Topiroxostat The metabolism of Glimepiride can be decreased when combined with Topiroxostat. Approved, Investigational Torasemide The therapeutic efficacy of Glimepiride can be decreased when used in combination with Torasemide. Approved Tranylcypromine Tranylcypromine may increase the hypoglycemic activities of Glimepiride. Approved, Investigational Trastuzumab Trastuzumab may increase the neutropenic activities of Glimepiride. Approved, Investigational Triamcinolone The therapeutic efficacy of Glimepiride can be decreased when used in combination with Triamcinolone. Approved, Vet Approved Trichlormethiazide The therapeutic efficacy of Glimepiride can be decreased when used in combination with Trichlormethiazide. Approved, Vet Approved Trimethoprim The metabolism of Glimepiride can be decreased when combined with Trimethoprim. Approved, Vet Approved Triptorelin The therapeutic efficacy of Glimepiride can be decreased when used in combination with Triptorelin. Approved, Vet Approved Troglitazone Troglitazone may increase the hypoglycemic activities of Glimepiride. Investigational, Withdrawn Trolamine salicylate Trolamine salicylate may increase the hypoglycemic activities of Glimepiride. Approved Trovafloxacin Trovafloxacin may increase the hypoglycemic activities of Glimepiride. Approved, Investigational, Withdrawn Ubidecarenone The therapeutic efficacy of Glimepiride can be increased when used in combination with Ubidecarenone. Approved, Investigational, Nutraceutical Valproic Acid The metabolism of Glimepiride can be decreased when combined with Valproic Acid. Approved, Investigational Valsartan The metabolism of Glimepiride can be decreased when combined with Valsartan. Approved, Investigational Varicella Zoster Vaccine (Live/Attenuated) The risk or severity of adverse effects can be increased when Glimepiride is combined with Varicella Zoster Vaccine (Live/Attenuated). Approved Venlafaxine Venlafaxine may increase the hypoglycemic activities of Glimepiride. Approved Vildagliptin Vildagliptin may increase the hypoglycemic activities of Glimepiride. Approved, Investigational Voglibose Voglibose may increase the hypoglycemic activities of Glimepiride. Approved, Investigational Voriconazole The serum concentration of Glimepiride can be increased when it is combined with Voriconazole. Approved, Investigational Vorinostat The therapeutic efficacy of Glimepiride can be decreased when used in combination with Vorinostat. Approved, Investigational Warfarin Glimepiride may increase the anticoagulant activities of Warfarin. Approved Yellow Fever Vaccine The risk or severity of adverse effects can be increased when Glimepiride is combined with Yellow Fever Vaccine. Approved, Investigational Zafirlukast The metabolism of Glimepiride can be decreased when combined with Zafirlukast. Approved, Investigational Zimelidine Zimelidine may increase the hypoglycemic activities of Glimepiride. Withdrawn Ziprasidone The therapeutic efficacy of Glimepiride can be decreased when used in combination with Ziprasidone. Approved - Food Interactions
- Avoid alcohol.
- Even though food reduces product absorption, the manufacturer recommends taking the product with the first meal of the day.
References
- Synthesis Reference
Suresh Kadam, Venkatasubramanian Tarur, Sanjay Naik, Sachin Gavhane, "Process for preparation of substantially pure glimepiride." U.S. Patent US20070082943, issued April 12, 2007.
US20070082943- General References
- Not Available
- External Links
- KEGG Drug
- D00593
- KEGG Compound
- C07669
- PubChem Compound
- 3476
- PubChem Substance
- 46508842
- ChemSpider
- 16740595
- ChEBI
- 5383
- ChEMBL
- CHEMBL1481
- Therapeutic Targets Database
- DAP000132
- PharmGKB
- PA449761
- RxList
- RxList Drug Page
- Drugs.com
- Drugs.com Drug Page
- Wikipedia
- Glimepiride
- ATC Codes
- A10BB12 — Glimepiride
- A10BB — Sulfonylureas
- A10B — BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
- A10 — DRUGS USED IN DIABETES
- A — ALIMENTARY TRACT AND METABOLISM
- A10BD — Combinations of oral blood glucose lowering drugs
- A10B — BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
- A10 — DRUGS USED IN DIABETES
- A — ALIMENTARY TRACT AND METABOLISM
- AHFS Codes
- 68:20.20 — Sulfonylureas
- FDA label
- Download (176 KB)
Clinical Trials
- Clinical Trials
Pharmacoeconomics
- Manufacturers
- Sanofi aventis us llc
- Accord healthcare inc
- Carlsbad technology inc
- Corepharma llc
- Dr reddys laboratories ltd
- Genpharm inc
- Invagen pharmaceuticals inc
- Mylan pharmaceuticals inc
- Ranbaxy laboratories ltd
- Teva pharmaceuticals usa inc
- Vintage pharmaceuticals llc
- Watson laboratories inc
- Watson laboratories inc florida
- Packagers
- Accord Healthcare
- Advanced Pharmaceutical Services Inc.
- Amerisource Health Services Corp.
- A-S Medication Solutions LLC
- Bryant Ranch Prepack
- Cardinal Health
- Carlsbad Technology Inc.
- Cobalt Pharmaceuticals Inc.
- Corepharma LLC
- Dispensing Solutions
- Diversified Healthcare Services Inc.
- Doctor Reddys Laboratories Ltd.
- Heartland Repack Services LLC
- Intas Pharmaceuticals Ltd.
- International Laboratories Inc.
- InvaGen Pharmaceuticals Inc.
- Ivax Pharmaceuticals
- Lake Erie Medical and Surgical Supply
- Murfreesboro Pharmaceutical Nursing Supply
- Mylan
- Nucare Pharmaceuticals Inc.
- PD-Rx Pharmaceuticals Inc.
- Perrigo Co.
- Pharmacy Service Center
- Physicians Total Care Inc.
- Prasco Labs
- Prepak Systems Inc.
- Ranbaxy Laboratories
- Rebel Distributors Corp.
- Resource Optimization and Innovation LLC
- Sandoz
- Sanofi-Aventis Inc.
- Southwood Pharmaceuticals
- Stat Scripts LLC
- Teva Pharmaceutical Industries Ltd.
- UDL Laboratories
- Vangard Labs Inc.
- Dosage forms
Form Route Strength Tablet Oral 1 mg Tablet Oral 2 mg Tablet Oral 4 mg Tablet Oral Tablet, film coated Oral Tablet Oral 1 mg/1 Tablet Oral 2 mg/1 Tablet Oral 3 mg/1 Tablet Oral 4 mg/1 Tablet Oral 6 mg/1 Tablet Oral 8 mg/1 Tablet Oral 3 mg - Prices
Unit description Cost Unit Amaryl 4 mg tablet 2.11USD tablet Amaryl 2 mg tablet 1.25USD tablet Glimepiride 4 mg tablet 1.25USD tablet Amaryl 1 mg tablet 0.88USD tablet Glimepiride 2 mg tablet 0.67USD tablet Glimepiride 1 mg tablet 0.42USD tablet DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.- Patents
Patent Number Pediatric Extension Approved Expires (estimated) US6150383 No 1996-06-19 2016-06-19 US US6211205 No 1996-06-19 2016-06-19 US US6303640 No 1996-08-09 2016-08-09 US US6329404 No 1996-06-19 2016-06-19 US US8071130 No 2008-06-08 2028-06-08 US US7538125 No 1996-06-19 2016-06-19 US US7700128 No 2007-01-30 2027-01-30 US US7358366 Yes 2000-10-19 2020-10-19 US
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 207 °C Not Available water solubility Insoluble Not Available logP 3.5 Not Available - Predicted Properties
Property Value Source Water Solubility 0.0347 mg/mL ALOGPS logP 3.03 ALOGPS logP 4.76 ChemAxon logS -4.2 ALOGPS pKa (Strongest Acidic) 2.23 ChemAxon pKa (Strongest Basic) -0.36 ChemAxon Physiological Charge 0 ChemAxon Hydrogen Acceptor Count 7 ChemAxon Hydrogen Donor Count 3 ChemAxon Polar Surface Area 131.66 Å2 ChemAxon Rotatable Bond Count 6 ChemAxon Refractivity 130.85 m3·mol-1 ChemAxon Polarizability 53.31 Å3 ChemAxon Number of Rings 3 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter No ChemAxon Veber's Rule No ChemAxon MDDR-like Rule Yes ChemAxon - Predicted ADMET features
Property Value Probability Human Intestinal Absorption + 0.986 Blood Brain Barrier + 0.7322 Caco-2 permeable - 0.6809 P-glycoprotein substrate Substrate 0.7501 P-glycoprotein inhibitor I Non-inhibitor 0.6556 P-glycoprotein inhibitor II Inhibitor 0.6124 Renal organic cation transporter Non-inhibitor 0.8241 CYP450 2C9 substrate Substrate 0.5661 CYP450 2D6 substrate Non-substrate 0.9116 CYP450 3A4 substrate Non-substrate 0.5978 CYP450 1A2 substrate Non-inhibitor 0.9045 CYP450 2C9 inhibitor Inhibitor 0.8949 CYP450 2D6 inhibitor Non-inhibitor 0.9231 CYP450 2C19 inhibitor Non-inhibitor 0.9025 CYP450 3A4 inhibitor Non-inhibitor 0.8309 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.8599 Ames test Non AMES toxic 0.6392 Carcinogenicity Non-carcinogens 0.7301 Biodegradation Not ready biodegradable 0.68 Rat acute toxicity 2.4158 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.7714 hERG inhibition (predictor II) Non-inhibitor 0.8263
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Taxonomy
- Description
- This compound belongs to the class of organic compounds known as benzenesulfonamides. These are organic compounds containing a sulfonamide group that is S-linked to a benzene ring.
- Kingdom
- Organic compounds
- Super Class
- Benzenoids
- Class
- Benzene and substituted derivatives
- Sub Class
- Benzenesulfonamides
- Direct Parent
- Benzenesulfonamides
- Alternative Parents
- Benzenesulfonyl compounds / Pyrroline carboxylic acids and derivatives / Sulfonylureas / N-acyl ureas / Organosulfonic acids and derivatives / Dicarboximides / Aminosulfonyl compounds / Azacyclic compounds / Organopnictogen compounds / Organic oxides show 2 more
- Substituents
- Benzenesulfonamide / Benzenesulfonyl group / Pyrroline carboxylic acid or derivatives / N-acyl urea / Ureide / Sulfonylurea / Dicarboximide / Pyrroline / Organic sulfonic acid or derivatives / Organosulfonic acid or derivatives show 17 more
- Molecular Framework
- Aromatic heteromonocyclic compounds
- External Descriptors
- sulfonamide, N-sulfonylurea, N-acylurea (CHEBI:5383)
Targets
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Voltage-gated potassium channel activity
- Specific Function
- This receptor is controlled by G proteins. Inward rectifier potassium channels are characterized by a greater tendency to allow potassium to flow into the cell rather than out of it. Their voltage ...
- Gene Name
- KCNJ11
- Uniprot ID
- Q14654
- Uniprot Name
- ATP-sensitive inward rectifier potassium channel 11
- Molecular Weight
- 43540.375 Da
References
- Song DK, Ashcroft FM: Glimepiride block of cloned beta-cell, cardiac and smooth muscle K(ATP) channels. Br J Pharmacol. 2001 May;133(1):193-9. [PubMed:11325810]
- Lawrence CL, Rainbow RD, Davies NW, Standen NB: Effect of metabolic inhibition on glimepiride block of native and cloned cardiac sarcolemmal K(ATP) channels. Br J Pharmacol. 2002 Jul;136(5):746-52. [PubMed:12086984]
- Bataille D: [Molecular mechanisms of insulin secretion]. Diabetes Metab. 2002 Dec;28(6 Suppl):4S7-13. [PubMed:12703060]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Phosphatidylinositol-4,5-bisphosphate binding
- Specific Function
- In the kidney, probably plays a major role in potassium homeostasis. Inward rectifier potassium channels are characterized by a greater tendency to allow potassium to flow into the cell rather than...
- Gene Name
- KCNJ1
- Uniprot ID
- P48048
- Uniprot Name
- ATP-sensitive inward rectifier potassium channel 1
- Molecular Weight
- 44794.6 Da
References
- Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
- Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
- Proks P, Reimann F, Green N, Gribble F, Ashcroft F: Sulfonylurea stimulation of insulin secretion. Diabetes. 2002 Dec;51 Suppl 3:S368-76. [PubMed:12475777]
- Bataille D: [Molecular mechanisms of insulin secretion]. Diabetes Metab. 2002 Dec;28(6 Suppl):4S7-13. [PubMed:12703060]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Inducer
- General Function
- Sulfonylurea receptor activity
- Specific Function
- Subunit of the beta-cell ATP-sensitive potassium channel (KATP). Regulator of ATP-sensitive K(+) channels and insulin release.
- Gene Name
- ABCC8
- Uniprot ID
- Q09428
- Uniprot Name
- ATP-binding cassette sub-family C member 8
- Molecular Weight
- 176990.36 Da
References
- Muller G, Hartz D, Punter J, Okonomopulos R, Kramer W: Differential interaction of glimepiride and glibenclamide with the beta-cell sulfonylurea receptor. I. Binding characteristics. Biochim Biophys Acta. 1994 May 11;1191(2):267-77. [PubMed:8172912]
- Kramer W, Muller G, Geisen K: Characterization of the molecular mode of action of the sulfonylurea, glimepiride, at beta-cells. Horm Metab Res. 1996 Sep;28(9):464-8. [PubMed:8911984]
- Kramer W, Muller G, Girbig F, Gutjahr U, Kowalewski S, Hartz D, Summ HD: The molecular interaction of sulfonylureas with beta-cell ATP-sensitive K(+)-channels. Diabetes Res Clin Pract. 1995 Aug;28 Suppl:S67-80. [PubMed:8529521]
Enzymes
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Steroid hydroxylase activity
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
- Gene Name
- CYP2C9
- Uniprot ID
- P11712
- Uniprot Name
- Cytochrome P450 2C9
- Molecular Weight
- 55627.365 Da
References
- Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
- Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
- Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Drug created on June 13, 2005 07:24 / Updated on April 23, 2018 22:57